Lipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cells

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Wang, Jie Wei ^a   Wan, Xing Yong ^a   Zhu, Hua Tuo ^a   Lu, Chao ^a   Yu, Wei Lai ^a   Yu, Chao Hui ^a   Shen, Zhe ^a   Li, You Ming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BIOLOGICAL MARKER; FATTY ACID; GLUTATHIONE; GLUTATHIONE DISULFIDE; PROTEIN P21; SMALL INTERFERING RNA; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; LEUPEPTIN; PRIMER DNA;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; FATTY LIVER; HUMAN; HUMAN CELL; L02 CELL LINE; LIPID PEROXIDATION; LIPID STORAGE; LIPOTOXICITY; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; GENE SILENCING; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

BASE SEQUENCE; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA PRIMERS; FATTY ACIDS, NONESTERIFIED; GENE SILENCING; HUMANS; LEUPEPTINS; NON-ALCOHOLIC FATTY LIVER DISEASE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84899762228     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096124     Document Type: Article

References (33)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023.
2. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285.
3. Chin Hee kim ZMY (2008, Octorber) Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. cleveland Clinic Journal of Medicine 75: 721-728.
4. C.P.Day (2002) pathogenesis of steatohepatitis. Best Practice & Research Clinical Gastroenterology 16: 663-678.
5. Mehta K, Van Thiel DH, Shah N, Mobarhan S (2002) Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 60: 289-293. (Pubitemid 35025794)
6. Seki S, Kitada T, Sakaguchi H (2005) Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res 33: 132-134. (Pubitemid 41799790)
7. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, et al. (April 2000)CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. The Journal of Clinical Investigation 105: 1067-1075. (Pubitemid 30217691)
8. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D (1996) Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 24: 200-208. (Pubitemid 26059117)
9. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14: 72-81.
10. Wu X, Zhang L, Gurley E, Studer E, Shang J, et al. (2008) Prevention of free fatty acid-induced hepatic lipotoxicity by 18b-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 47: 1905-1915. (Pubitemid 351945558)
11. Cortez-Pinto H, Zhi Lin H, Qi Yang S, Odwin Da Costa S, Diehl AM (1999) Lipids up-regulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology 116: 1184-1193. (Pubitemid 29203029)
12. Sherr CJ, Roberts JM (1999 Jun 15) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501-12. (Pubitemid 29297917)
13. Gartel AL, Radhakrishnan SK (2005 May 15) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65(10):3980-5. (Pubitemid 40775632)
14. Rodriguez R, Meuth M (2006) Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 17: 402-412. (Pubitemid 43049492)
15. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825. (Pubitemid 23346378)
16. Torbenson M, Yang SQ, Liu HZ, Huang J, Gage W, et al. (2002) STAT-3 Overexpression and p21 Up-Regulation Accompany Impaired Regeneration of Fatty Livers. The American Journal of Pathology 161: 155-161. (Pubitemid 34760781)
17. Zhang X, Zhou D, Strakovsky R, Zhang Y, Pan YX (22 December 2011) Hepatic cellular senescence pathway genes are induced through histone modifications in a diet-induced obese rat model. Am J Physiol Gastrointest Liver Physiol 302: 558-564.
18. Tomita K, Teratani T, Suzuki T, Oshikawa T, Yokoyama H, et al. (2012) p53/ p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice. J Hepatol 57: 837-843.
19. Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, et al. (2007) Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 133: 80-90. (Pubitemid 47031146)
20. Aravinthan A, Scarpini C, Tachtatzis P, Verma S, Penrhyn-Lowe S, et al. (2013 Mar) Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J Hepatol 58(3):549-56. doi: 10.1016/j.jhep.2012.10.031.
21. Passos JF, Nelson G, Wang C, Richter T, Simillion C, et al. (2010) Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol 6: 347.
22. Roskams T, Yang SQ, Koteish A, Durnez A, DeVos R, et al. (2003) Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 163: 1301-1311. (Pubitemid 37175079)
23. Yang S, Koteish A, Lin H, Huang J, Roskams T, et al. (2004) Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology 39: 403-411. (Pubitemid 38222181)
24. Parekh S, Anania FA (2007) Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132: 2191-2207. (Pubitemid 46693752)
25. Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV, et al. (2007) A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165: 106-116. (Pubitemid 46072796)
26. Alexandrova A, Petrov L, Georgieva A, Kirkova M, Kukan M (2008) Effects of proteasome inhibitor, MG132, on proteasome activity and oxidative status of rat liver. Cell Biochem Funct 26: 392-398. (Pubitemid 351613182)
27. Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, et al. (1997 Jun 24) Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A 94(13):6629-34.
28. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, et al. (2004) Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 106: 635-643. (Pubitemid 38797577)
29. Guo N, Peng Z (2013) MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol 9: 6-11.
30. Chu JH, Wang H, Ye Y, Chan PK, Pan SY, et al. (2011) Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells. World J Gastroenterol 17: 2379-2388.
31. Masgras I, Carrera S, de Verdier PJ, Brennan P, Majid A, et al. (2012) Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. J Biol Chem 287: 9845-9854.
32. Aravinthan A, Pietrosi G, Hoare M, Jupp J, Marshall A, et al. (2013) Hepatocyte expression of the senescence marker p21 is linked to fibrosis and an adverse liver-related outcome in alcohol-related liver disease. PLoS One 8: e72904.
33. Nakajima T, Nakashima T, Okada Y, Jo M, Nishikawa T, et al. (2010) Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non-alcoholic fatty liver disease: Comparison with telomere-specific quantitative FISH and p21 immunohistochemistry. Pathol Int 60: 175-183.